US moves psychedelics into research mode, and India’s pharma opportunity just widened

Mental illness trials are speeding up in the US

The US is rapidly accelerating research into psychedelics for mental illness, signaling a major shift from counterculture to mainstream R&D. That change should push India to revisit its drug policies and build the ecosystem needed for responsible progress. With deep cultural ties to altered states, India can lead by funding research centers, developing therapies, and modernizing legal frameworks.